Pentoxifylline NDC 0615-8511

NDC codes

FDA NDC Directory

Product NDC (as listed)0615-8511Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00615-8511Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0615-8511-39	00615851139	30 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0615-8511-39)Marketed from Jun 26, 2024

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pentoxifylline
Generic name (nonproprietary): pentoxifylline
Active ingredients: Pentoxifylline — 400 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: NCS HealthCare of KY, LLC dba Vangard Labs
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074878
Marketing start: Jan 15, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Hematologic Activity Alteration (Physiologic effect)
Identifiers: Product ID 0615-8511_e3966eca-d995-479b-b2a3-4fd6eea51cb1SPL ID e3966eca-d995-479b-b2a3-4fd6eea51cb1SPL set ID bd2f2672-62cd-4e77-8b0b-782f5d06198bRxCUI 312301UNII SD6QCT3TSU
Pharmacologic class: Blood Viscosity Reducer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400615851139 followed by a unit qualifier and the quantity

Package 00615-8511-39. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 22, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Pentoxifylline Extended-Release Tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-Release Tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 074878

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 074878
Product	Strength	Form · route	Labeler	Product NDC
Pentoxifylline	Pentoxifylline 400 mg/1	Tablet, Extended releaseOral	ANI Pharmaceuticals, Inc.	70954-668